Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

6 terminated/withdrawn out of 36 trials

Success Rate

81.3%

-5.3% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

27%

7 of 26 completed trials have results

Key Signals

1 recruiting7 with results

Enrollment Performance

Analytics

N/A
10(100.0%)
10Total
N/A(10)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials
NCT06820060Active Not Recruiting

Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus

Role: lead

NCT06824129Active Not Recruiting

Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR

Role: lead

NCT05305534Completed

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study

Role: lead

NCT06645236Not ApplicableRecruiting

DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

Role: lead

NCT05092438Completed

QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study 001

Role: lead

NCT05347745Not ApplicableCompleted

Therascreen® KRAS RGQ PCR Kit

Role: lead

NCT05162547Completed

Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay

Role: lead

NCT06360757Terminated

Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19)

Role: lead

NCT06745414Completed

Clinical Performance of QIAstat-Dx® Gastrointestinal Panel 2

Role: lead

NCT06681025Completed

Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients

Role: lead

NCT05348187Not ApplicableCompleted

Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

Role: lead

NCT05347797Not ApplicableCompleted

Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit

Role: lead

NCT05360225Completed

Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit

Role: lead

NCT05155553Completed

QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study

Role: lead

NCT05657275Not ApplicableCompleted

Impact on the Use of Antibiotics of a Multimodal Algorithm for the Diagnosis and Management of Acute Community-acquired Pneumonia in the Emergency Room

Role: collaborator

NCT05733559Completed

QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study

Role: lead

NCT05235958Not ApplicableCompleted

VascuFit: Exercise and Vascular Aging

Role: collaborator

NCT01543113Not ApplicableCompleted

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Role: collaborator

NCT05109247Completed

Prediction of Spontaneous Onset of Labor at Term

Role: collaborator

NCT04243031Withdrawn

QuantiFERON Access Clinical Performance Study Protocol

Role: lead